This is single - arm study to explore the safety and efficacy of iparomlimab and tuvonralimab (QL1706) combined with chemotherapy for treating her2-negative, low PD-L1 expressing, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma
Aged 18-75 years, gender is not limited;
Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;
HER2-negative by immunohistochemistry (IHC);
low PD-L1 expression status (CPS < 5);
Allergic to any trial drug and its excipients, or serious allergy history, or contraindication of the trial drug;
Cardiovascular and cerebrovascular events that are not well controlled;
Has received systematic treatment with Chinese patent medicine or immunomodulatory drugs (including thymosin, interferon, interleukin, except for local use for ascites control) before the first administration within 2 weeks;
Have a history of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, acute lung disease, or systemic disease with poor control (including but not limited to diabetes, hypertension, etc.);
Qilu Hospital of Shandong University
Lead sponsor